GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Taro Pharmaceutical Industries Ltd (NYSE:TARO) » Definitions » 3-Year FCF Growth Rate

Taro Pharmaceutical Industries (Taro Pharmaceutical Industries) 3-Year FCF Growth Rate : -63.10% (As of Dec. 2023)


View and export this data going back to 1987. Start your Free Trial

What is Taro Pharmaceutical Industries 3-Year FCF Growth Rate?

Taro Pharmaceutical Industries's Free Cash Flow per Share for the three months ended in Dec. 2023 was $-0.10.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was -63.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.

During the past 13 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of Taro Pharmaceutical Industries was 73.80% per year. The lowest was -131.20% per year. And the median was 4.50% per year.


Competitive Comparison of Taro Pharmaceutical Industries's 3-Year FCF Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Taro Pharmaceutical Industries's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Taro Pharmaceutical Industries's 3-Year FCF Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Taro Pharmaceutical Industries's 3-Year FCF Growth Rate distribution charts can be found below:

* The bar in red indicates where Taro Pharmaceutical Industries's 3-Year FCF Growth Rate falls into.



Taro Pharmaceutical Industries 3-Year FCF Growth Rate Calculation

This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.


Taro Pharmaceutical Industries  (NYSE:TARO) 3-Year FCF Growth Rate Explanation

Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.


Taro Pharmaceutical Industries 3-Year FCF Growth Rate Related Terms

Thank you for viewing the detailed overview of Taro Pharmaceutical Industries's 3-Year FCF Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Taro Pharmaceutical Industries (Taro Pharmaceutical Industries) Business Description

Traded in Other Exchanges
Address
14 Hakitor Street, P.O. Box 10347, Haifa Bay, Haifa, ISR, 2624761
Taro Pharmaceutical Industries Ltd produces, researches, develops, and markets pharmaceutical products. Its primary focus includes semi-solid formulations, such as creams and ointments, and other dosage forms such as liquids, capsules, and tablets. The company is engaged in the dermatological and topical, cardiovascular, neuropsychiatric, and anti-inflammatory therapeutic categories. Geographically, it derives a majority of its revenue from the United States and also has a presence in Canada, Israel, and Other Countries.
Executives
Sun Pharma Global Inc 10 percent owner
Sun Pharmaceutical Industries Ltd 10 percent owner, other: Affiliated Party 17/B, MAHAL INDUSTRIAL ESTATE, MAHAKALI CAVES ROAD, ANDEHERI (EAST) K7 400 093
Alkaloida Chemical Co Exclusive Group Ltd. 10 percent owner KABAY JANOS UT 29., TISZAVASVARI K5 4440
Franklin Resources Inc 10 percent owner FRANKLIN RESOURCES INC, ONE FRANKLIN PARKWAY, SAN MATEO CA 94403

Taro Pharmaceutical Industries (Taro Pharmaceutical Industries) Headlines

From GuruFocus

Taro to Announce First Quarter Results on July 27, 2021

By Business Wire Business Wire 07-21-2021

Taro to Announce Full Year Results on May 19, 2021

By Business Wire Business Wire 05-12-2021

Taro Launches Specialty Generic Deferiprone Tablets, 500mg in the U.S.

By Business Wire Business Wire 09-28-2020

Taro to Announce Second Quarter Results on October 28, 2021

By Business Wire Business Wire 10-21-2021

Taro to Release Full Year Results on May 23, 2023

By Business Wire Business Wire 05-18-2023

Taro Appoints New Chief Financial Officer

By Business Wire Business Wire 12-01-2021

Taro Completes Acquisition of Alchemee

By Business Wire Business Wire 03-01-2022

Taro Announces Resignation of Chief Financial Officer

By Business Wire Business Wire 07-14-2021